Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag scPharmaceuticals secures $125M non-dilutive financing from Perceptive Advisors for debt repayment and FUROSCIX commercialization.

flag scPharmaceuticals Inc. announces an underwritten public offering of common stock or pre-funded warrants, with option for underwriters to buy 15% more within 30 days. flag The company also secures up to $125M non-dilutive financing from Perceptive Advisors, a life-sciences investor. flag Proceeds from both transactions will be used for debt repayment and ongoing commercialization of FUROSCIX.

4 Articles

Further Reading